Molecular remission of chronic myeloid leukaemia in a patient with hepatitis and a second kidney transplant.

Saved in:

Bibliographic Details
Title:	Molecular remission of chronic myeloid leukaemia in a patient with hepatitis and a second kidney transplant.
Authors:	Castillo-Rama, M.¹, Grande, C.², Martínez-Sánchez, P.², Olavarria, E.³, Marín, D.³, Paz-Artal, E.¹, Andrés, A.⁴, Morales, J. M.⁴ josemariamoralesc@yahoo.es
Source:	Nefrologia. Dec2009, Vol. 29 Issue 6, p604-607. 4p. 3 Charts, 2 Graphs.
Subjects:	CHRONIC myeloid leukemia, HEPATITIS, KIDNEY transplant patients, ONCOGENES, PROTEIN-tyrosine kinases, DISEASE remission, HEPATITIS C, CARDIOVASCULAR agents, PATIENTS
Abstract (English):	Chronic myeloid leukemia (CML) is a myeloproliferative disorder characterized by clonal expansion of cells in the myeloid line, expressing the BCRABL fusion protein responsible for the oncogenic effect of CML. The current frontline therapy in CML is the BCR-ABL tyrosine kinase inhibitor, Imatinib. Although this drug has been shown to improve survival in CML patients, its role in the context of a transplant setting has not been widely described in the literature. We report on the long term molecular remission of CML in a 55 year old man with a second renal transplant who is hepatitis C virus positive, and has associated cardiovascular and immunological risk factors. [ABSTRACT FROM AUTHOR]
Abstract (Spanish):	La leucemia mieloide crónica (LMC) es una enfermedad mieloproliferativa caracterizada por la expansión clonal de células mieloides que expresan la proteína de fusión BCR-ABL, responsable de los efectos oncogénicos de la LMC. La terapia actual en el tratamiento de LMC es el inhibidor de la BCR-ABL tirosín-kinasa, imatinib. Aunque este fármaco ha demostrado mejorar la supervivencia en pacientes con LMC, su papel en el contexto del trasplante renal no ha sido ampliamente descrito en la literatura. Presentamos un caso de remisión molecular de LMC en un varón de 55 años con un segundo trasplante renal, hepatitis C y con riesgos cardiovasculares e inmunológicos asociados. [ABSTRACT FROM AUTHOR]
	Copyright of Nefrologia is the property of Revista Nefrologia and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database:	MedicLatina

Description
Abstract:	Chronic myeloid leukemia (CML) is a myeloproliferative disorder characterized by clonal expansion of cells in the myeloid line, expressing the BCRABL fusion protein responsible for the oncogenic effect of CML. The current frontline therapy in CML is the BCR-ABL tyrosine kinase inhibitor, Imatinib. Although this drug has been shown to improve survival in CML patients, its role in the context of a transplant setting has not been widely described in the literature. We report on the long term molecular remission of CML in a 55 year old man with a second renal transplant who is hepatitis C virus positive, and has associated cardiovascular and immunological risk factors. [ABSTRACT FROM AUTHOR]
ISSN:	02116995